key: cord-0867952-isw3cgej
authors: Thiruchelvam, Kaeshaelya; Kow, Chia Siang; Hadi, Muhammad Abdul; Hasan, Syed Shahzad
title: The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review
date: 2021-06-30
journal: Expert review of anti-infective therapy
DOI: 10.1080/14787210.2021.1949984
sha: 74ce73f4cd6e9ed569ce40bd1903389d7bfdd352
doc_id: 867952
cord_uid: isw3cgej

OBJECTIVE: We systematically reviewed the evidence of published original research to determine the role of remdesivir in the management of patients with COVID-19 and a moderate-to-severe course of illness. METHODS: A systematic search of articles was conducted in scientific databases, with the latest update in May 2021. This paper systematically reviewed the clinical evidence available (randomized controlled trials, compassionate use studies, and case reports) on the use of remdesivir for patients with moderate or severe COVID-19. RESULTS: A total of eleven studies were included: four studies based on compassionate use of remdesivir, three randomized, double-blind, placebo-controlled, multicentre trials, three randomized, open-label, phase III trials, and one case report. Clinical improvement and mortality rates in patients who used remdesivir varied across studies. CONCLUSION: Given the current evidence, there is insufficient data to confidently recommend the use of remdesivir alone for the treatment of adult hospitalized patients with moderate-to-severe COVID-19. However, remdesivir may be considered along with an anti-inflammatory agent in patients with pneumonia, on oxygen support, provided there is close monitoring of clinical and laboratory parameters and adverse events.

Coronavirus disease-19 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic since its first emergence in the city of Wuhan, China in December 2019 [1] . The pandemic has plummeted many parts of the world into a protracted economic, medical, and social crisis [2] . Patients with COVID-19 present with a wide spectrum of severity ranging from asymptomatic, to mild disease (i.e. absence of pneumonia or mild pneumonia), and to severe/critical life-threatening disease manifested as acute respiratory disease syndrome (ARDS) or multiorgan dysfunction [3] [4] [5] . Patients with severe illness typically present with dyspnea and low blood oxygen levels, requiring oxygen therapy or intensive respiratory support with mechanical ventilation [6] . Given the lethality of COVID-19 in which the case fatality rate ranged from approximately 1% to 12% [7] , it is crucial to identify an effective treatment for patients with a severe course of illness, since oxygen supplementation and supportive care may not be sufficient to prevent deaths [8] . In addition, effective treatment is also required for patients with moderate course of illness to prevent further deterioration in their clinical progress.

The disease has garnered attention in the research and medical forefronts, and several candidate drugs have been evaluated for their effectiveness against SARS-CoV-2 infection; they include antimalarials (chloroquine and hydroxychloroquine), systemic corticosteroids (dexamethasone), convalescent plasma, protease inhibitors (lopinavir/ritonavir), interleukin-6 inhibitors (tocilizumab and sarilumab), and favipiravir, a broad-spectrum inhibitor of viral ribonucleic acid (RNA) polymerase [9] [10] [11] [12] [13] [14] . However, there has been little or no success with almost all of these therapies in patients with COVID-19.

Remdesivir (GS-5734) is a broad-spectrum antiviral with activity against a range of RNA virus families including coronaviruses [15] and has been a strong contender in combating COVID-19. Remdesivir is an inhibitor of the viral RNAdependent RNA polymerase, which demonstrates antiviral activity against the Middle East respiratory syndrome (MERS-CoV) and SARS-CoV [16] . In vitro testing of remdesivir during the early outbreak of COVID-19 in the Wuhan Institute of Virology has demonstrated its potential to inhibit SARS-CoV -2. Later, remdesivir has been reported to be successfully used in a patient with COVID-19 in the United States of America (USA) in January 2020 [17] . Remdesivir which is an adenosine analog, exhibits antiviral activity by incorporating into nascent viral RNA chains, resulting in premature termination of RNA synthesis [18] .

Due to its promising effects in preclinical models, the utilization of remdesivir for the treatment of patients with COVID-19 has been of huge interest. It is timely to evaluate the current evidence to assess the trade-off between efficacy and safety of remdesivir for patients with a moderate-tosevere course of COVID-19. Therefore, we aim to systematically review the evidence of published original research involving human subjects, including randomized controlled trials (RCTs), studies of individual compassionate use, and case reports, to determine the role of remdesivir in the management of COVID-19 patients with a moderate-to-severe course of illness.

Studies were included if they were original studies, of any study design (case report, case series, non-randomized controlled trial, randomized controlled trial) and investigated the compassionate use of remdesivir or use of remdesivir in clinical trials, and reported outcomes related to clinical improvement and mortality in hospitalized, adult patients with moderate-to-severe COVID-19. Moderate illness was defined based on evidence of lower respiratory disease during clinical assessment or imaging, with oxygen saturation ≥94% on room air at sea level. Severe illness was defined based on the need for respiratory support (oxygen therapy, noninvasive or invasive ventilatory support), extracorporeal membrane oxygenation, or admission to intensive care unit (ICU).

Studies were excluded if there was no involvement of human subjects, if there was no identifiable information on the clinical severity of included participants with COVID-19, if there was involvement of pediatric patients or obstetric patients, and if there were no reported outcomes related to clinical improvement and mortality.

A literature search was performed in August 2020, updated in January 2021 and again in May 2021, in the following electronic databases: PubMed (United States National Library of Medicine), Cochrane Central Register of Controlled Trials, and the World Health Organization (WHO) COVID-19 Database, to identify potential articles for inclusion. Google Scholar was also searched to identify articles not indexed in scientific databases. We also checked the reference lists of all potential studies identified to avoid omission of relevant studies.

Searches were constructed by using the search terms '2019-nCoV', 'COVID-19,' 'SARS-CoV-2,' 'remdesivir,' and 'GS-5734.' Searches were limited to 'adults (limit: 18+ years),' 'humans,' and '1 January 2020 up to 30 May 2021 .' An initial screen of titles and abstracts was undertaken by the primary investigator (KT) to identify articles meeting the inclusion criteria. Subsequently, the full texts of the selected studies were retrieved. Two investigators (KT and CSK) independently assessed the full texts of possible articles for inclusion in this review to validate the results.

The study design, number of participants, study setting, disease severity, use of co-interventions, follow-up duration, participants' assessments, clinical and laboratory data, study endpoints, recovery or improvement rates, rates of adverse events, rates of discontinuation of treatment, and mortality rates, were extracted. The extracted data from all the included studies were subsequently collected and tabulated using a form developed by the primary investigator (KT) that was verified by the second investigator (CSK).

Our search yielded 1876 unique records. After application of eligibility criteria and subsequent full-text examination, eleven studies were included in this review ( Figure 1 ). Table 1 summarizes the findings of the included studies in chronological order. We included a total of four studies based on compassionate use of remdesivir [8, [19] [20] [21] , three randomized, doubleblind, placebo-controlled, multicentre trials [22] [23] [24] [25] , three randomized, open-label, phase III trials [26] [27] [28] , and one case report which we felt was of clinical interest [29] . Remdesivir was provided by its manufacturer, Gilead Sciences, and therapy was uniform across all studies for a total duration of 10 days (based on its efficacy established in an earlier study by Mulangu et al. [30] ), i.e. 200 mg intravenous loading dose on day 1, followed by 100 mg daily administration from days 2 to 9; except the study by Goldman et al. {26 ]which compared the effectiveness of remdesivir as a 5-day or a 10-day course. the study by Aiswarya et al. [21] adjusted the dosing regimen for dialysis-dependent patients (2.5 mg/kg [dry weight] intravenously up to a maximum dose of 100 mg on day 1, 4 hours before the dialysis session, with subsequent doses up to a maximum of 6 doses given 4 hours before each dialysis session for 9 days to complete the 10-day duration). The trial by Spinner et al. [27] consisted of three arms where the effectiveness of remdesivir, each as a 5-day and a 10-day course, was compared with standard care. With an exception of the case report [29] , the compassionate use study by Pasquini et al. [20] , and the randomized, open-label multicentre trial by the WHO Solidarity Trial Consortium [28] , all studies utilized an ordinal scale to evaluate the clinical improvement of patients based on a pre-specified pointdecrease from baseline to discharge, albeit with varying scale interpretations across the included studies.

The compassionate use study by Grein et al. [19] is the first to report the clinical benefits of remdesivir in patients with COVID-19. This study, which was sponsored by Gilead Sciences, the manufacturer of remdesivir, involved 53 hospitalized patients with COVID-19; details of the study population are presented in Table 1 . The study reported that the overall cumulative incidence of improvement at day 28 was 84.0% (95% confidence interval (CI) 70-99%) and improvement was better among those receiving noninvasive ventilation or were younger than 50 years, compared to those receiving invasive ventilation or were 70 years and over, respectively. However, the authors reanalyzed the cumulative incidence of improvement at day 28 upon initiation of remdesivir using a competing-risk approach whereby death was deemed a treatment failure and reported cumulative incidence of improvement as 74.0% (95% CI 55-86%).

Antinori et al. [8] also reported a compassionate use study in Italy among 35 patients with COVID-19 in the ICU and 18 patients in the Infectious Diseases Ward (IDW) who had severe illness. All concomitant treatments were permitted except for lopinavir/ritonavir as per recommendation by Gilead Sciences. Rate of clinical improvement by day 28 was higher among patients admitted to IDW (88.2%) compared to patients admitted to the ICU (38.9%). Again, due to the nature of this study, it was not possible to include a control arm to preclude the possibility that patients may have improved regardless of any treatment. Furthermore, some patients (numbers not reported) had previously been administered with lopinavir/ ritonavir and hydroxychloroquine before their inclusion in this study, and thus it was difficult to draw definitive conclusions due to such confounding factors.

In contrast to the aforementioned study, a compassionate use study by Pasquini et al. [20] reported possible mortality Most common adverse events in ≥2 patients in the remdesivir group: Constipation [22] , hypoalbuminaemia [20] , hypokalaemia [18] , anemia [18] , thrombocytopenia [16] & increased total bilirubin [15] . Most common adverse events in ≥ patients in the placebo group: Hypoalbuminaemia [12] , constipation [12] , anemia [12] , hypokalaemia [11] , increased aspartate aminotransferase [9] , points from baseline on the ordinal scale), time to recovery as an improvement from a baseline score of 2 to 5 to a score of 6 or 7, the time to modified recovery (defined as a baseline score improvement of 2 to 4 to a score of 5 to 7, or from a score of 5 to a score of 6 or 7), and death from any cause. All-cause mortality at day 28 for the 5-day group was 1% (95% CI: 0.0-2.6), 2% for the 10-day group (95% CI: 0.0-3.6) and 2% for standard care (95% CI: 0.1-4.1), using Kaplan-Meier estimates.

All 9 deaths through day 28 (2 or 1% in the 5-day group, 3 or 2% in the 10-day group and 4 or 2% in the standard care group) occurred among those aged 64 years and older, and none were attributed to remdesivir treatment.

(Continued ) 15 June 2020 In May 2020, remdesivir was authorized for emergency use (EUA) in the treatment of suspected or laboratoryconfirmed severe COVID-19 among hospitalized adults and children. This authorization allowed for remdesivir to be distributed and administered intravenously in the USA [6] . However following this recommendation on June 15, the FDA has warned health care professionals that administering remdesivir concomitantly with hydroxychloroquine or chloroquine phosphate may reduce the antiviral activity of remdesivir and is not recommended [42] . The initial approval in May 2020 was based on the preliminary findings of the trial conducted by the National Institutes of Health. This emergency use authorization (EUA) will be effective until termination or revision, or if the EUA is revoked based on not meeting statutory requirements given changing circumstances pertaining the use of remdesivir [6] . benefits with the use of remdesivir in critically ill patients with COVID-19. The study included 51 patients admitted into the ICUs receiving mechanical ventilation with confirmed SARS-CoV-2 infection, of which 25 were treated with remdesivir, while the remaining 26 did not have access to remdesivir. Concomitant therapy with hydroxychloroquine and tocilizumab was permitted, but not with lopinavir/ritonavir. Tocilizumab use was reported to be more commonly used among patients treated with remdesivir (28% versus 7%; p = 0.075). However, this study did not report outcomes related to clinical improvement. Aiswarya et al. [21] investigated the compassionate use of remdesivir in 48 patients with end-stage renal disease (dialysis-dependent) and moderate-to-severe COVID-19. At the end of the remdesivir therapy, 33 patients (68.8%) showed an improvement in oxygen requirement in the ordinal scale score for respiratory support. This improvement was significant in patients requiring a lower modality of oxygen support (score 1-3) at admission. Patients on high-flow oxygen and noninvasive ventilation at the initiation of remdesivir therapy did not benefit. In addition, it was reported that early administration of remdesivir within 48 hours of hospital admission shortened the duration of hospitalization by a mean of 5.5 days (P = 0.001).

Hillaker et al. [29] described a case report of an otherwise healthy 40-year-old man with COVID-19. The patient showed good clinical progression upon administration of remdesivir, albeit previous administration of hydroxychloroquine and azithromycin to control symptoms while waiting for approval of compassionate remdesivir use. This case report suggested that late initiation of remdesivir could be effective in the treatment of patients with COVID-19.

Wang et al. [22] reported a randomized, double-blinded, placebo-controlled trial among 237 hospitalized patients with COVID-19, which was a continuation of their previous study [16] establishing promising in-vitro activity of remdesivir against SARS-CoV-2. The trial found that remdesivir did not significantly improve the time to clinical improvement (hazard ratio (HR) 1.23; 95% CI 0.87-1.75 in the intention-to-treat population and HR 1.27; 95% CI 0.89-1.80 in the per-protocol population), although it was numerically shorter for those treated with remdesivir within 10 days of symptom onset than those treated with placebo. Despite not statistically significant, the duration of use of invasive mechanical ventilation was also numerically shorter in the remdesivir group as opposed to the placebo group. It is important to note that their study permitted the use of concomitant therapy including lopinavir/ritonavir at baseline in 42 (18.0%) patients.

The US National Institute of Allergy and Infectious Diseases (NIAID)'s global Phase III trial by Beigel et al. [25] published their final report recently. This is a randomized, doubleblinded, placebo-controlled trial which included 1,062 hospitalized patients with COVID-19; their preliminary findings had been reported previously [23] . The patients were stratified based on disease severity (mild/moderate and severe). Patients were permitted concomitant treatment as per the respective standard of care in trial sites. However, in the absence of concomitant treatment, experimental treatment and off-label use of marketed medications were not permitted. The authors reported an overall shorter recovery time (regardless of disease severity) among patients in the remdesivir group compared to those in the placebo group (a median of 10 days compared to 15 days; recovery risk ratio [RR] 1.29; 95% CI 1.12-1.49). Using a proportional odds model and upon adjustment for actual disease severity, patients with remdesivir were more likely than those receiving placebo to have clinical improvement at day 15 (odds ratio [OR] 1.5; 95% CI 1.2-1.9). In the severe disease stratum (957 patients), median recovery time was 11 days compared to 18 days (recovery RR 1.31; 95% CI 1.12-1.52). In the subgroup analysis, the reduced time to recovery was only statistically significant among patients who were on low-flow oxygen at baseline (ordinal score 5) (recovery RR 1.45; 95% CI 1.18-1.79). Among the subgroup of patients on mechanical ventilation or ECMO at baseline, there was no statistically significant difference on the time to recovery between remdesivir and placebo (recovery RR 0.98; 95% CI 0.70-1.36).

Goldman et al. [26] reported an open-label randomized phase III trial (sponsored by Gilead Sciences) to determine the shortest yet effective duration of treatment with remdesivir by comparing a 5-day course with a 10-day standard course (the SIMPLE trial). The study permitted concomitant supportive therapy at the discretion of the investigators. In their preliminary findings involving 397 hospitalized patients with severe COVID-19, the authors reported no significant differences in both groups after adjustment of imbalances in baseline clinical status. By day 14, clinical improvement of ≥2 points on the ordinal scale were reported in 64.0% and 54.0% of the patients in the 5-day and 10-day group, respectively. However, upon adjustment for clinical status at baseline, there was no significant difference in both groups (baseline-adjusted difference in proportions of −6.3%; 95% CI −15.4-2.8) (p = 0.14).

Spinner et al. [27] reported an open-label, three-arm, randomized phase III trial among hospitalized patients with moderate COVID-19 (i.e. hospitalized with evidence of pulmonary infiltrates and oxygen saturation >94% on room air). This trial investigated the effectiveness of remdesivir comparing a 5-day and a 10-day remdesivir course, with standard care at day 11 of treatment. Though initial study protocol was designed to evaluate the primary end-point of the proportion of patients discharged by day 14, the protocol was subsequently amended to modify the primary end-point to the assessment of clinical status on day 11 based on a 7-point ordinal scale. In addition, the trial initially permitted concomitant use of medications deemed as 'local care' but did not permit their use upon subsequent protocol amendment, although some patients previously had concurrent therapy. Patients in the 5-day remdesivir group had statistically significantly higher odds of better clinical status distribution on the 7-point scale by day 11 than those receiving standard care (OR 1.65; 95% CI 1.09-2.48). There was no significant difference in clinical status distribution between patients in the 10-day remdesivir group and the standard care group (p = 0.18). There were also no significant differences between the 5-or 10-day remdesivir groups and standard care group for any of the exploratory end-points by day 11, including the time to 2-point or greater improvement in clinical status, time to 1-point or greater improvement in clinical status, time to recovery, time to modified recovery, and time to discontinuation of oxygen support. Subgroup analysis revealed no difference between the remdesivir group and placebo group in proportions of patients with 1-point or greater improvement in clinical status among the patients with supplemental low-flow oxygen therapy as well as those without supplemental low-flow oxygen therapy.

The open-label multicentre Solidarity trial by the WHO reported outcomes on in-hospital mortality, as well as the initiation of mechanical ventilation and hospital duration, with several investigational agents [28] . This study included 11,330 patients from 405 hospitals in 30 countries [28] . Trial drugs included remdesivir, hydroxychloroquine, lopinavir, and interferon, where a 10-day duration of remdesivir with a 200 mg intravenous loading dose, followed by a 9-day regimen of 100 mg was used; doses of other drugs are reported in the summary table. There were no placebos used in this study. None of the trial drugs, including remdesivir, reduced the requirement for ventilation for patients who were already on it. In addition, none of the trial drugs including remdesivir reduced duration of hospitalization.

Finally, the most recent findings from the clinical trials were reported by Kalil et al. [24] as part of a double-blind randomized, placebo-controlled, trial sponsored by The National Institute of Allergy and Infectious Diseases. Their trial included two arms where patients were assigned to either receive remdesivir and baricitinib, or remdesivir and a placebo; remdesivir dose was similar to the abovementioned studies, whereas baricitinib was administered as a 4 mg daily dose orally (two 2 mg tablets) or via a nasogastric tube for 14 days. If the glomerular filtration rate was <60 mL/min, the dose was halved to 2 mg daily. Given that this was a multicentre trial, they permitted the use of concomitant treatments if trial sites had written policies where off-label COVID-19 treatment was allowed; but in its absence, this was not permitted. Patients with combination treatment recovered a median of 1 day sooner than patients who received remdesivir and placebo (median 7 days vs. 8 days; recovery RR 1.16; 95% CI 1.01-1.32; p = 0.03). Odds of improvement in clinical status at day 15 as per the ordinal scale was greater in the combination group than the control group (OR for improvement 1.3; 95%CI: 1.0-1.6). Subgroup analyses based on stratification of disease severity (moderate vs. severe) at the time of randomization reported that combination of remdesivir and baricitinib significantly improved time to recovery for those with severe disease (recovery RR 1.32; 95% CI 1.00-1.75) but not for those with moderate disease (recovery RR 1.11; 95% CI 0.95-1.30). Median time for recovery among those receiving noninvasive ventilation or high-flow oxygen was 10 days in the combination group and 18 days in the control group (recovery RR 1.51; 95% CI 1.10-2.08).

Common adverse events observed in patients receiving remdesivir included hepatotoxicity (elevated serum levels of total bilirubin, aspartate aminotransferase, and alanine aminotransferase) [8, 19, [21] [22] [23] , hypotension [19, 23] , diarrhea [19] , rash [19] , constipation [22, 26] , nausea [26, 27] , hypoalbuminemia [22] , hypokalemia [22, 27] , anemia [22, 23] , thrombocytopenia [22] , hyperglycemia [23] and headache [27] . Serious adverse events reported in patients using remdesivir included acute kidney injury (AKI [4.0% to 22.8%]; 49% of patients treated with remdesivir required continuous renal replacement therapy but the cause of kidney failure was not stated and could be due to multiorgan failure from COVID-19) [8, 19, 20, 23] , respiratory failure or ARDS (5.2% to 10.0%) [22, 23, 26] , cardiopulmonary failure (5.0%) [22] , multiple-organ dysfunction syndrome (4.0%) [19] , septic shock (4.0%) [19] and hypotension (4.0%) [19] . Although hepatotoxicity and AKI have been reported as the most common adverse events associated with the use of remdesivir, it is challenging to establish causality as these adverse events can be attributed to the pathogenesis of COVID-19 itself [8, 31] . In randomized controlled trials [22, 23] , common adverse events associated with the placebo group included hepatotoxicity (elevated serum levels of aspartate aminotransferase and total bilirubin) [22] , hypotension [23] , dyslipidemia [22] , hypoalbuminemia [22] , constipation [22] , anemia [22] , and hypokalemia [22] . Serious adverse events in the placebo group included respiratory failure or ARDS [22, 23] , cardiopulmonary failure [22] , and AKI [23] .

Adverse events could also be attributed to concomitant medications which were permitted in some studies [8, [21] [22] [23] [24] 26] . In the trial by Kalil et al. [24] which included the addition of baricitinib in one arm, and the use of a placebo in another, serious adverse events that occurred in both arms included anemia, hyperglycemia, AKI, and decreased lymphocyte count; the proportion of patients with serious or nonserious venous thromboembolism were similar in both arms. The concomitant use of lopinavir/ritonavir with remdesivir in 18.0% of patients at baseline in the study by Wang et al. [22] and possibly in some or all of the patients in the study by Beigel et al. [23] (their study permitted concomitant therapies as per respective standard care for trial sites) could have resulted in hepatotoxicity; lopinavir/ritonavir is a potent inhibitor of the enzyme cytochrome P450 3A (CYP3A) and remdesivir is metabolized by CYP3A. Furthermore, hepatotoxicity, nausea, vomiting, and diarrhea are common adverse drug reactions associated with lopinavir/ritonavir [32] .

Treatment discontinuation due to serious adverse events was another major limitation in the included studies. Remdesivir was discontinued in 4 patients (8.0%) in the study by Grein et al. [19] , in 18 (12.0%) and 4 (5.0%) patients from the remdesivir and placebo groups, respectively, in the study by Wang et al. [22] , in 4 ICU patients due to AKI and overall in 37.0% patients due to adverse events in the study by Antinori et al. [8] , in 49 patients before day 10 in the study by Beigel et al. [23] and in 9 (4.0%) patients from the 5-day group and 20 (10.0%) patients from the 10-day group in the study by Goldman et al. [26] . In the study by Spinner et al., [27] remdesivir was discontinued in 8 (4%) patients in the 10-day group, 4 (2%) patients in the 5-day group, but none in the standard care group. Serious adverse events leading to discontinuation in patients receiving remdesivir included behavioral change [21] , respiratory failure or ARDS [22, 23, 26] , cardiopulmonary failure [22] , AKI [8, 19, 23] , hypotension [23] , multiple-organ failure [19] , transaminitis [8, 19, 23] , and maculopapular rash [19] . On the other hand, serious adverse events leading to discontinuation in the placebo group included respiratory failure or ARDS [22] and cardiopulmonary failure [22] . These data are available in detail in Table 1 .

Mortality rates in patients who used remdesivir varied across studies. The patient from the case report by Hillaker et al. [29] survived and were successfully discharged. The compassionate use study by Grein et al. reported that 7 of 53 patients (13.0%) died upon completion of remdesivir therapy, but their findings received some criticism from the research fraternity [19, 33] . They claimed mortality rate should have been 22.0% based upon 7 patients who died but with a denominator of 32 (instead of 53) which represented the total number of patients who were discharged or had died, i.e. 25 and 7 patients, respectively [19, 33] . The other compassionate use study by Antinori et al. reported that 3 of the 4 ICU patients who discontinued remdesivir due to AKI died and that 4 ICU patients (22.2%) who received remdesivir died by day 10 of treatment, and 8 ICU patients (44.4%) died by day 28 of treatment, while 1 IDW patient died by day 10 of treatment [8] . The compassionate use study by Aiswarya et al. [21] reported that 10 patients (20.8%) died during hospitalization; 7 patients had their remdesivir initiated less than 48 hours since admission while the remaining 3 patients had their remdesivir initiated more than 48 hours since admission.

The compassionate use study by Pasquini et al. [20] reported findings that were focused on mortality as an outcome. Survival analysis by Kaplan-Meier curves observed that the mortality rate was significantly lower among patients treated with remdesivir than in untreated patients (56.0% versus 92.3%; p < 0.001). In addition, multivariate analysis observed that treatment with remdesivir was the only factor associated with survival (odds ratio 3.506; 95% CI 1.768-6.954; p < 0.001). Nevertheless, it should be noted that there may be presence of selection bias in the study since patients with mild renal impairment or who received inotropic support had no access to remdesivir treatment. However, the authors argued that patient selection may not bias toward better outcomes since most of the ICU patients experienced clinical deterioration, resulting in death in 74.5% of included patients.

Mortality rates were not statistically significant between the two treatment groups in all three of the randomized, double-blinded, placebo-controlled trials by Wang et al. [22] (22 patients or 14.0% died in the remdesivir group vs. 10 or 13.0% in the placebo group; difference 1.1%; 95% CI −8.1-10.3), Beigel et al. [23] (HR for death 0.73; 95% CI 0.52-1.03), and Kalil et al. [24] (HR for death 0.60; 95% CI 0.39-1.09), respectively. Beigel et al. [23] reported that Kaplan-Meier estimates of 15-day and 29-day mortality were 6.7% and 11.9%, and 11.4% and 15.2%, in the remdesivir and placebo groups, respectively. However, among the subgroup of patients who were on oxygen supplementation but did not require high-flow oxygen or ventilatory support (either noninvasive or invasive), there was a statistically significant 29-day mortality benefit (4.0% versus 12.7%, HR 0.30, 95% CI 0.14-0.64). In the randomized, open-label, phase III trial by Goldman et al., [26] 16 of 200 patients (8.0%) in the 5-day group and 21 of 197 patients (10.7%) in the 10-day group died by day 14. The randomized, open-label trial by Spinner et al. [27] reported that all-cause mortality using Kaplan-Meier estimates at day 28 was 1% for the 5-day group (95% CI: 0.0-2.6), 2% for the 10-day group (95% CI: 0.0-3.6), and 2% for standard care (95% CI: 0.1-4.1). The Solidarity trial [28] by the WHO reported that remdesivir did not indefinitely reduce mortality (RR 0.95; 95% CI 0.81-1.11), even in the subgroup analyses.

The use of remdesivir has garnered attention in the management of COVID-19 since March 2020 [34] . There was a variation in terms of eligibility of participants across studies in terms of dependence on oxygen support, which may not allow generalizability of results based on oxygen dependence level. A major confounder in some studies was the use of concomitant medications and prior therapies with potential effects against SARS-CoV-2, thus raising concerns about the conclusions made on the efficacy of remdesivir [8, [20] [21] [22] [23] [24] [25] [26] [27] 29] . In addition, the use of an ordinal scale in most of the included studies is not ideal for demonstration of clinical improvement in patients with COVID-19 since decisions to discharge patients or to place patients on respiratory support, etc. may have been influenced by other considerations in addition to patients' clinical progress.

We included four compassionate use studies to present evidence in emergencies where all other therapeutic approaches were exhausted especially in both the studies by Antinori et al. [8] and Pasquini et al. [, 20] respectively, during the outbreak in Italy. Although the study by Antinori et al. [8] was without a control group, a median recovery time of 12 days upon remdesivir administration and the recovery of higher number of patients outside the ICU suggested that remdesivir may be beneficial for patients with pneumonia who are not critically ill. The study by Grein et al. [19] had limitations including variation across trial sites for institutional treatment protocols and thresholds, small sample size, a lack of a placebo-controlled group, a lack of viral load data, and censored data for deceased patients. Although these limitations were acknowledged by the authors, the study received mixed reviews from the research and medical community [19, 33] . Apart from the concerns mentioned above, the medical fraternity raised questions about the false-positive results implied by the authors with regard to the efficacy of remdesivir due to non-generalizability of the results to patients with severe COVID-19, since 12 of 53 patients were not receiving high-grade oxygen support. However, the authors maintained their stance on generalizing their results to patients with severe COVID-19, as their study population comprised hospitalized patients receiving supplemental oxygen or with hypoxia [33] . The study by Pasquini et al. [20] compared the risk of mortality in hospitalized patients treated with remdesivir with their counterparts not treated with remdesivir, i.e. control group, and reported a higher mortality rate (74.5%) compared to other studies. The authors attributed the relatively high mortality rate to data collection during the initial 3 weeks of the pandemic when their ICU capacity was under extreme pressure. Their hospital was restructured to admit only patients who had confirmed SARS-CoV-2 infections with a fourfold increase in ICU beds, but with an unmet need of ventilators, specialized nurses, and doctors during the study period. Another limitation in the study was the exclusion of patients with mild renal impairment or those who commenced inotropic support, and therefore the possibility for selection bias. Nevertheless, the authors argued that since majority of the included patients with COVID-19 experienced clinical deterioration upon admission into ICU, patient selection in the remdesivir cohort may not lead to better clinical outcomes. The authors also reported late initiation of remdesivir at a median of 18 days upon symptom onset, although other studies [8, 19] have not depicted better clinical outcomes with earlier initiation. The study by Aiswarya et al. [21] reported the safe compassionate use of remdesivir in dialysisdependent patients (who had been excluded in clinical trials), and improvement in oxygen requirement was observed in patients requiring a lower modality of oxygen support at admission.

The case report [29] suggested positive outcomes in the use of remdesivir. However, given the low level of evidence associated with the nature of this study design, the findings cannot be generalized. This study was discussed in our paper as it was paramount in the initiation of larger studies (e.g. clinical trials) and the successful request to the US Food and Drug Administration (FDA) for remdesivir as an emergency investigational new drug (eIND) [21, 29] . It is also important to acknowledge the difficulties associated with obtaining approval and the use of remdesivir in the case study by Hillaker et al. [29] which resulted in delayed treatment. The overwhelming request of remdesivir from the manufacturer put a strain on their supply and thus on 22 March 2020, the manufacturer halted their compassionate use program but committed to fulfilling the delivery of pre-approved requests [35] . However, Gilead Sciences is currently working closely with regulatory agencies globally to provide emergency access to remdesivir [6, [36] [37] [38] .

The randomized, double-blinded, placebo-controlled trials presented mixed findings [22, 23] . It is important to note that the trial by Wang et al. [22] failed to achieve target enrollment due to marked reductions in new patients with COVID-19 in China and restrictions in terms of hospital bed availability, resulting in potentially insufficient power to detect significant differences between both groups. This study also aimed to assess the clinical benefits from the time of symptom onset to initiation of remdesivir, but failed to do so due to the limitations; otherwise, the findings may inform the optimal time to the initiation of remdesivir. Overall, the study found that remdesivir was well tolerated with no new safety concerns [22] . The data and safety monitoring board from the trial by Beigel et al. [23] allowed the results of their study to be unblinded to the trial team members which may have resulted in measurement bias. According to the authors, the publication of the paper on preliminary results was based on immediate importance for care of patients with COVID-19 within and outside the trial; they concluded that the use of remdesivir is indicated for hospitalized patients with COVID-19 who require supplemental oxygen therapy, in combination with other therapeutic approaches [23] . The final report presented consistent findings to the preliminary report, whereby a 10-day course of remdesivir was more effective than placebo in shortening the time to recovery among patients with COVID-19, especially those who were on low-flow oxygen at baseline [25] . Treatment with remdesivir may have prevented progression to a more serious form of respiratory disease, depicted by lower incidence of new oxygen use and lower proportion of patients with serious adverse events due to respiratory failure. New in the final report was that adjustment was made for glucocorticoid use, and that the benefits in terms of recovery persisted, suggesting that the benefit of glucocorticoids could be additive to remdesivir's benefit. They stated that treatment of patients with moderate-to-severe COVID-19 with an antiviral alone may not be sufficient given the high mortality rates despite the use of remdesivir. This is where findings of the trial by Kalil et al. [24] which compared use of remdesivir and baricitinib vs. remdesivir and a placebo, are interesting to highlight. They reported that the use of remdesivir and baricitinib was superior compared to use of remdesivir alone, based on time to recovery given that the former significantly accelerated improvement in clinical status; this was the case for patients receiving noninvasive ventilation as well as high-flow oxygen. Serious adverse events were lower in incidence in the group that received baricitinib compared to those who received remdesivir alone. The authors also highlighted that dexamethasone, which has been recommended in clinical practice after the RECOVERY trial [14] , has a longer half-life, and reduces inflammation via a broad-pathway approach and may be associated with immunosuppression, whereas baricitinib has a short half-life and reduces inflammation by acting on targeted critical pathways, with less immunosuppression.

In the open-label RCT by Goldman et al. [26] , the authors reported that the trend toward better outcomes in patients treated with 5 days of remdesivir could be due to the fact that patients in the 10-day arm had more severe illness which necessitated mechanical ventilation with high-flow oxygen, which has been known to worsen the prognosis. An openlabel design was used due to the unavailability of matched placebo vials which had been allocated to other trials. Since patients could be discharged when medically indicated and this precluded completion of the full 10-day course of remdesivir, only 44.0% of patients in the 10-day group completed their course. The authors also claimed that their results could not be extrapolated to patients with COVID-19 who are critically ill and receiving mechanical ventilation, given that only few patients in the trial were receiving mechanical ventilation prior to the initiation of remdesivir [26] .

Similarly, the open-label nature in the RCT by Spinner et al. [27] was due to an insufficient number of placebo-containing vials to support this trial. Although the authors reported that patients who received remdesivir for 5 days had significantly higher odds of better clinical status distribution 11 days after treatment initiation compared to those who received standard care, the effect size was of uncertain clinical importance. This could have been due to the open-label study design, whereby discharge decisions could have been influenced by the assigned duration for remdesivir treatment, which peaked upon the end of the dosing period (day 6 for the 5-day group and day 11 for the 10-day group) [27] .

Finally, the Solidarity trial [28] by the WHO presents the recent evidence on the use of remdesivir, where remdesivir did not have a significant effect in hospitalized patients with COVID-19. None of the drugs including remdesivir effectively reduced in-hospital mortality overall and in any subgroups, neither did it reduce ventilation or duration of hospitalization. This was a large multicentre trial and adherence remained 94% to 96% midway through treatment, which included 2% to 6% on crossover. The study protocol did not specify disease severity, although subgroup analyses are provided elsewhere [28] .

Given the current evidence, there is insufficient data to confidently recommend routine initiation of remdesivir alone for the treatment of hospitalized patients with moderate-tosevere COVID-19. However, remdesivir may be considered along with an anti-inflammatory agent (e.g. baricitinib) in adult or adolescent (≥12 years) patients with pneumonia and on oxygen support, provided there is close monitoring of clinical and laboratory parameters and adverse events upon administration of remdesivir. Most of the current evidence for remdesivir has emerged from its clinical use in patients with moderate-to-severe COVID-19 in a hospital setting or as emergency use in critically ill patients with COVID-19 and therefore, its use should be restricted in this patient population under close clinical supervision and monitoring.

Ongoing clinical trials will provide better understanding of the role of remdesivir in improving outcomes in other subgroup of patients with COVID-19.

Firstly, it is important to note that most of the national regulatory agencies across the world including the FDA in the USA, the European Medicines Agency (EMA) in Europe, the Therapeutic Goods and Administration (TGA) in Australia, the Japanese Ministry of Health, Labour and Welfare (MHLW) in Japan, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom and the Health Sciences Authority (HSA) in Singapore have conditionally approved/approved the use of remdesivir in COVID-19 patients under specific conditions (Table 2 ) [6,37-41] (conditional approvals pending safety data) [35] .

The inclusion of all RCTs available at the time of publication ensures highly credible evidence in concluding the effectiveness and safety of the use of remdesivir. Nevertheless, it should be highlighted that there is a lack of investigation on the impact of remdesivir on viral load in the RCTs reviewed in this paper. In addition, it is still not known with certainty that mechanically ventilated patients benefit from the use of remdesivir. At present, data on the effectiveness and safety of remdesivir alone is not compelling to allow for its routine use in hospitalized patients with moderate-to-severe COVID-19. However, the use of remdesivir with an anti-inflammatory agent (e.g. baricitinib) might be considered in hospitalized adults or adolescents with COVID-19 ( 12 years) with pneumonia and on oxygen support, in order to accelerate their recovery, provided that there is close monitoring of adverse events, and clinical and laboratory parameters upon administration of remdesivir. The initiation of remdesivir is considered optimal as soon as possible upon hospitalization and it is recommended for a 10-day duration, with a 200 mg intravenous loading dose on day 1, followed by a 100 mg daily administration [8, [19] [20] [21] [22] [23] [24] [26] [27] [28] [29] [30] .

The safety profile of remdesivir is not fully established at this stage as the suggestive incidence of adverse events and mortality may or may not be linked to its use. Therefore, careful monitoring is required and the following monitoring recommendations should be implemented [22, 23, 27] : daily monitoring of vital signs and blood pressure; clinical laboratory testing for hepatic, renal, blood, and lipid profiles every 3 days; and a 12-lead electrocardiogram upon 7 days of use.

There is insufficient evidence to conclusively recommend the use of remdesivir in pregnant women, children (<12 years), and older people (≥60 years) with multiple underlying comorbidities. However, Gilead Sciences has made a statement that compassionate use requests can be made exclusively for children (<12 years) and pregnant women with confirmed COVID-19 and with severe manifestations of the disease, if necessary [35] . Given the recent recommendation by the US FDA, remdesivir is not recommended to be concomitantly administered with hydroxychloroquine or chloroquine phosphate [42] . It is also important to consider that the manufacturer is moving toward an expanded access program for all future institutional use of remdesivir (with an exception of clinical trials), but the procedure of accessing remdesivir is expected to be similarly challenging to the individual compassionate use procedure [29, 35] . Therefore, consideration must also be given to the accessibility of remdesivir, and arrangements for approvals to acquire remdesivir should be made as soon as possible if it is deemed potentially useful for patients based on respective hospital standards of care.

Results from other ongoing trials will further improve our current understanding on the role of remdesivir in patients with COVID-19. The second SIMPLE trial by Gilead Sciences which is a three-arm RCT aims to determine the efficacy and safety of remdesivir therapy for 5 and 10 days versus standard of care. In addition, their REMDECTA trial is being conducted and aims to determine the efficacy and safety of remdesivir in combination with an anti-inflammatory drug, tocilizumab [43] . The French Institute of Health and Medical Research (INSERM) is conducting a study to evaluate remdesivir and other potential treatments based on a master protocol developed by the WHO [35] . When available, the results of these trials must be carefully considered and may shift the paradigm of treatment with remdesivir in hospitalized patients with moderate-to-severe COVID-19. Consideration should also be given to the recent development of dry powder remdesivir by researchers at the University of Texas [44] . This formulation can be considered for use in non-hospitalized COVID-19 patients, to increase accessibility to the drug. The dry powder inhalation will be deliverable at lower doses and allows for direct action in the lungs, which is the primary infection site for patients with respiratory symptoms.

This study was not funded.

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers

The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control

M Millions had Risen out of poverty. Coronavirus is pulling them back. The New York Times

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Care for critically Ill patients with COVID-19

Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Is it worth the wait? Should chloroquine or hydroxychloroquine be allowed for immediate use in CoViD-19?

Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Dexamethasone in hospitalized patients with covid-19

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

First case of 2019 novel coronavirus in the United States

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Compassionate use of remdesivir for patients with severe covid-19

Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU

Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance

This study reported the compassionate use of remdesivir in patients with COVID-19 undergoing hemodialysis

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

This is an important RCT that led to a series of other studies investigating the use of remdesivir

Remdesivir for the treatment of covid-19 -preliminary report. Reply

Baricitinib plus remdesivir for hospitalized adults with covid-19

Remdesivir for the treatment of covid-19 -final report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

Repurposed antiviral drugs for covid-19 -interim WHO solidarity trial results

Delayed initiation of remdesivir in a COVID-19-positive patient

This case report was included in the paper as it suggests effective late initiation of remdesivir

A randomized, controlled trial of Ebola virus disease therapeutics

Liver injury in COVID-19: management and challenges

National Institutes of Health. Lopinavir/Ritonavir and Other HIV Protease Inhibitors | coronavirus Disease COVID-19

Compassionate use of remdesivir in Covid-19

Management of SARS-CoV-2 infection: recommendations of the polish association of epidemiologists and infectiologists as of march 31 2020

Gilead sciences statement on access to remdesivir outside of clinical trials

Japanese regulator approves Gilead's remdesivir to treat Covid-19

Australia's first COVID-19 treatment approved

EMA starts rolling review of remdesivir for COVID-19

UK grants early access to Gilead's remdesivir for Covid-19

Singapore approves Gilead's remdesivir to treat Covid-19

Remdesivir by gilead sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment

pose/advancing-global-health/covid-19/remdesivir-clinical-trials 44. FIERCE Pharma. Researchers develop dry powder remdesivir to strike COVID-19 where it counts

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. 

KT drafted the manuscript, and KT, CSK, MAH, and SSH equally contributed to the revision of the manuscript in its final form. All authors read and approved the final manuscript.